Dr. John Cush RheumNow

3 years 11 months ago

Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21 https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG

https://bit.ly/3wt5M1V

Guselkumab Use Improves Anemia in Treatment of PsA: Dr. Robert Chao

3 years 11 months ago

Robert B Chao, MD doctorRBC

3 years 11 months ago

Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed

Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthrit…

Robert B Chao, MD doctorRBC

3 years 11 months ago

Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Am…

Dr. Rachel Tate uptoTate

3 years 11 months ago

SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX

Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthr…

Olga Petryna DrPetryna

3 years 11 months ago

Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ

Richard Conway RichardPAConway

3 years 11 months ago

Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5

Richard Conway RichardPAConway

3 years 11 months ago

Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc

Updates on New Treatments for SpA: Drs. Antoni Chan and Laura Coates

3 years 11 months ago

Guselkumab in Psoriatic Arthritis

Pedro Castillo

3 years 11 months ago

D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.

ACR21 Best Abstracts - Day 1

Jack Cush, MD

3 years 11 months ago

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.